Blog
RSS FeedPosted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 18 Jan 2022
Discussion paper and online questionnaire for information session on a potential pan-Canadian formulary
18 January 2022 - On 18 January 2022, the advisory panel and CADTH will host an information session on the panel’s ...
Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...
Posted by Michael Wonder on 01 Dec 2021
Lilly Canada concludes successful negotiation with the Pan-Canadian Pharmaceutical Alliance for Baqsimi (glucagon nasal powder)
30 November 2021 - Lilly Canada is pleased to announce the completion of a successful negotiation with the pan-Canadian Pharmaceutical Alliance ...
Posted by Michael Wonder on 27 Nov 2021
What happened to the promise of universal pharmacare?
25 November 2021 - Canada is the only developed country in the world with a universal health care system that ...
Posted by Michael Wonder on 27 Nov 2021
It’s time to better support the three million Canadians with a rare disease
25 November 2021 - After finding out her private health insurer would no longer pay for a drug helping with ...
Posted by Michael Wonder on 03 Nov 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta
3 November 2021 - First provincial public listing secured for both asthma medications. ...
Posted by Michael Wonder on 18 Oct 2021
Alnylam receives positive reimbursement recommendation from the CADTH for use of Givlaari for the treatment of acute hepatic porphyria in adults
18 October 2021 - Givlaari reduces chronic pain, improves quality of life and is the first and only therapy proven ...
Posted by Michael Wonder on 12 Oct 2021
Outdated criteria for drug plan reimbursement obstruct evidence based care
12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...
Posted by Michael Wonder on 28 Sep 2021
Onpattro (patisiran) now reimbursed in Canada for the treatment of hereditary transthyretin mediated amyloidosis
28 September 2021 - Onpattro is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life ...
Posted by Michael Wonder on 26 Sep 2021
Manitoba family calling for province to cover life-changing drug
26 September 2021 - A new drug called Trikafta could be a life-changing treatment option for people living with cystic ...
Posted by Michael Wonder on 25 Sep 2021
Ontario providing access to life changing treatment for cystic fibrosis patients
24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...
Posted by Michael Wonder on 23 Sep 2021
Canada should negotiate a fairer share of drug R&D costs
23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...
Posted by Michael Wonder on 20 Sep 2021
Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 02 Sep 2021
A collaborative pilot on current awareness alerts for disinvestment and horizon scanning
31 August 2021 - In 2019, members of the Health Technology Assessment international Interest Group for Disinvestment and Early Awareness and ...